PPARG and metabolic dysfunction-associated steatotic liver disease: The results of this post-hoc analysis provide evidence that a dual PPAR agonist with an affinity for the PPAR-α and PPAR-γ may have a beneficial effects on NAFLD and subsequent risk of fibrosis in patients with T2DM.